|
|
AbbVie Files Preliminary Proxy Statement on Schedule 14A
NORTH CHICAGO, ILLINOIS, U.S.A., March 9, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a preliminary proxy statement on Schedule 14A with the U.S. Securities and
Exchange Commission ("SEC").
AbbVie makes available free of charge on its website its Annual... Lire le communiqué |
|
| |
|
| |
|
|
Use these links to rapidly review the document
TABLE OF CONTENTS
TABLE OF CONTENTS1
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie and Boehringer Ingelheim announce global collaboration on promising
immunology compounds
- Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy
over ustekinumab in Phase 2 clinical studies with a potential for quarterly
dosing
- Potential to become best-in-class treatment in psoriasis with additional Phase
2 development in... Lire le communiqué |
|
| |
|
| |
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K
CURRENT REPORT
Pursuant to Section 13 or 15d of the
... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Form 8-K
NORTH CHICAGO, Illinois, February 22, 2016 -- AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Current Report on Form 8-K with the U.S. Securities and Exchange
Commission ("SEC"), announcing that the Board of Directors has approved and
adopted Amended and Restated By-laws to implement proxy... Lire le communiqué |
|
| |
|
| |
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10K
MARK ONE
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15d OF THE SECURITIES EXCHANGE ACT
... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Form 10-K
NORTH CHICAGO, ILLINOIS, U.S.A., Feb. 19, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed an Annual Report on Form 10-K for the fiscal year ended December 31, 2015
with the U.S. Securities and Exchange Commission ("SEC").
AbbVie makes available free of charge on its website its Annual Report... Lire le communiqué |
|
| |
|
| |
